Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in adjuvant HER2-positive breast cancer
NCT01358877Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2011
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial of pertuzumab in breast cancer, sponsored by Roche. Started Nov 2011; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01358877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01358877.